|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 July 2001, Vol. 98, No. 2, pp. 280-286
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Clinical and virologic characteristics of chronic active
Epstein-Barr virus infection
Hiroshi Kimura,
Yo Hoshino,
Hirokazu Kanegane,
Ikuya Tsuge,
Takayuki Okamura,
Keisei Kawa, and
Tsuneo Morishima
From the Department of Pediatrics, Nagoya University Graduate
School of Medicine, Department of Health Science, Nagoya University
School of Medicine, Nagoya, Japan; Department of Pediatrics, Faculty of
Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan;
Department of Pediatrics, Osaka Medical Center, and Research Institute
for Maternal and Child Health, Osaka, Japan.
Thirty patients with chronic active Epstein-Barr virus (CAEBV)
infection were analyzed. The study group included 18 male and 12 female
patients, ranging in age from 5 to 31 years with a mean age of 14.2 years. Not all patients had high titers of EBV-specific antibodies, but
all patients had high viral loads in their peripheral blood (more than
102.5 copies/µg DNA). Fifty percent of the patients
displayed chromosomal aberrations, and 79% had monoclonality of EBV.
Patients were divided into 2 clinically distinct groups, based on
whether the predominantly infected cells in their peripheral blood were
T cells or natural killer (NK) cells. Over a 68-month period of
observation, 10 patients died from hepatic failure, malignant lymphoma,
or other causes. Patients with T-cell CAEBV had a shorter survival time
than those with NK-cell type of disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Iwata, K. Wada, S. Tobita, K. Gotoh, Y. Ito, A. Demachi-Okamura, N. Shimizu, Y. Nishiyama, and H. Kimura
Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection
J. Gen. Virol.,
January 1, 2010;
91(1):
42 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Cohen, H. Kimura, S. Nakamura, Y.-H. Ko, and E. S. Jaffe
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
Ann. Onc.,
September 1, 2009;
20(9):
1472 - 1482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Strowig, C. Gurer, A. Ploss, Y.-F. Liu, F. Arrey, J. Sashihara, G. Koo, C. M. Rice, J. W. Young, A. Chadburn, et al.
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
J. Exp. Med.,
June 8, 2009;
206(6):
1423 - 1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Oyama, K. Yamamoto, N. Asano, A. Oshiro, R. Suzuki, Y. Kagami, Y. Morishima, K. Takeuchi, T. Izumo, S. Mori, et al.
Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Clin. Cancer Res.,
September 1, 2007;
13(17):
5124 - 5132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Ogawa, M Harigai, T Akashi, K Nagasaka, F Suzuki, S Tominaga, and N Miyasaka
Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
Ann Rheum Dis,
December 1, 2006;
65(12):
1667 - 1669.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Iwatsuki, M. Satoh, T. Yamamoto, T. Oono, S. Morizane, M. Ohtsuka, Z.-G. Xu, D. Suzuki, and K. Tsuji
Pathogenic link between hydroa vacciniforme and epstein-barr virus-associated hematologic disorders.
Arch Dermatol,
May 1, 2006;
142(5):
587 - 595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Williams and D. H. Crawford
Epstein-Barr virus: the impact of scientific advances on clinical practice
Blood,
February 1, 2006;
107(3):
862 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe
Pathobiology of Peripheral T-cell Lymphomas
Hematology,
January 1, 2006;
2006(1):
317 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Martro and V. Ausina
The role of Epstein-Barr virus in pleural effusions of unknown aetiology: an interesting clinical perspective
Eur. Respir. J.,
October 1, 2005;
26(4):
566 - 568.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. T. Thijsen, R. Luderer, J. M. H. van Gorp, S. J. G. Oudejans, and A. W. J. Bossink
A possible role for Epstein-Barr virus in the pathogenesis of pleural effusion
Eur. Respir. J.,
October 1, 2005;
26(4):
662 - 666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Heslop
Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas
Hematology,
January 1, 2005;
2005(1):
260 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Katano, M. A. Ali, A. C. Patera, M. Catalfamo, E. S. Jaffe, H. Kimura, J. K. Dale, S. E. Straus, and J. I. Cohen
Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation
Blood,
February 15, 2004;
103(4):
1244 - 1252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-I. Imadome, M. Shirakata, N. Shimizu, S. Nonoyama, and Y. Yamanashi
CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation
PNAS,
June 24, 2003;
100(13):
7836 - 7840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Oyoshi, H. Nagata, N. Kimura, Y. Zhang, A. Demachi, T. Hara, H. Kanegane, Y. Matsuo, T. Yamaguchi, T. Morio, et al.
Preferential Expansion of V{gamma}9-J{gamma}P/V{delta}2-J{delta}3 {gamma}{delta} T Cells in Nasal T-Cell Lymphoma and Chronic Active Epstein-Barr Virus Infection
Am. J. Pathol.,
May 1, 2003;
162(5):
1629 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Savoldo, M. H. Huls, Z. Liu, T. Okamura, H.-D. Volk, P. Reinke, R. Sabat, N. Babel, J. F. Jones, J. Webster-Cyriaque, et al.
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection
Blood,
December 1, 2002;
100(12):
4059 - 4066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
